Viewing nowLyrica CR Extended-Release Tablets 330 mg (Pregabalin)
Pregabalin 330mg
Tablet · Prescription medication
Viatris Korea Co., Ltd.

MFDS item code 201802991 · Approved 2018.07.18 · Insurance code 073400270
Treatment of peripheral neuropathic pain in adults
This medication is used to treat pain caused by peripheral neuropathy in adult patients. Peripheral neuropathic pain mainly appears in various forms, such as numbness, tingling, and burning sensations in the hands and feet, and this medication helps to alleviate these symptoms and improve the quality of life for patients. It helps control pain due to nerve damage, reducing discomfort and aiding comfort.
This drug is administered once daily after the evening meal. It must be swallowed whole and must not be split, crushed, or chewed. As this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to ‘3. Patients with renal impairment’) If you forget to take this drug within 1 hour after the evening meal, it is recommended that you have a snack before bedtime and take this drug. If you forget to take this drug before bedtime, it is recommended that you eat breakfast and take this drug. If you forget to take this drug after breakfast, it is recommended that you take it at the usual time, that is, after the evening meal. The starting dose of this drug may be 165 mg once daily. Depending on the response and tolerability of each patient, the dose may be increased to 330 mg once daily after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 660 mg once daily. 1. Switching from Lyrica Capsules to Lyrica CR Extended-Release Tablets When switching from Lyrica Capsules to Lyrica CR Extended-Release Tablets, take the morning dose of Lyrica Capsules as prescribed on the day of the switch, and start taking Lyrica CR Extended-Release Tablets after the evening meal. Total daily dose of Lyrica Capsules (administered 2 or 3 times daily)d: 75 mg/day → Lyrica CR Extended-Release Tablets dose (once daily): 82.5 mg/day Total daily dose of Lyrica Capsules (administered 2 or 3 times daily)d: 150 mg/day → Lyrica CR Extended-Release Tablets dose (once daily): 165 mg/day Total daily dose of Lyrica Capsules (administered 2 or 3 times daily)d: 225 mg/day → Lyrica CR Extended-Release Tablets dose (once daily): 247.5 mga/day Total daily dose of Lyrica Capsules (administered 2 or 3 times daily)d: 300 mg/day → Lyrica CR Extended-Release Tablets dose (once daily): 330 mg/day Total daily dose of Lyrica Capsules (administered 2 or 3 times daily)d: 450 mg/day → Lyrica CR Extended-Release Tablets dose (once daily): 495 mgb/day Total daily dose of Lyrica Capsules (administered 2 or 3 times daily)d: 600 mg/day → Lyrica CR Extended-Release Tablets dose (once daily): 660 mgc/day a. 247.5 mg= 3×82.5 mg tablets once daily b. 495 mg= 3×165 mg tablets once daily c. 660 mg=2×330 mg tablets once daily d. Refer to the prescribing information for ‘Lyrica Capsules’ 2. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 3. Patients with renal impairment Use of this drug is not recommended in patients with creatinine clearance below 30 mL/min or in patients receiving hemodialysis. These patients should receive Lyrica Capsules. In view of dose-dependent adverse reactions, the dose should be adjusted in patients with impaired renal function, as pregabalin is primarily excreted by the kidneys. Dosage adjustment in patients with renal impairment is based on creatinine clearance [Table 2]. To use the dosage table below, the patient's creatinine clearance (mL/min) value is required. Creatinine clearance (mL/min) can be estimated from serum creatinine (mg/dL) using the Cockcroft-Gault equation. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) / 72 x serum creatinine concentration (serum creatinine, mg/dL) *For women, multiply the result obtained from the above equation by 0.85. Next, determine the recommended total daily dose for patients with normal renal function (CLcr≥60 mL/min) based on the indication, and then adjust the dose according to renal function by referring to [Table 2]. (Example: A patient with postherpetic neuralgia and normal renal function [CLcr≥60 mL/min] starting this drug receives pregabalin 165 mg once daily. Therefore, a patient with renal impairment and creatinine clearance of 50 mL/min receives 82.5 mg once daily.) Creatinine clearance (CLcr) ≥60: Total daily dose of pregabalin (mg/day) 165, 330, 495a, 660b; administration: once daily Creatinine clearance (CLcr) 30-60: Total daily dose of pregabalin (mg/day) 82.5, 165, 247.5c, 330; administration: once daily Creatinine clearance (CLcr) <30 or hemodialysis: Administer Lyrica Capsules a. 495 mg= 3×165 mg tablets once daily b. 660 mg= 2×330 mg tablets once daily c. 247.5 mg=3×82.5 mg tablets once daily 4. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 6. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so it is important to carefully monitor mood changes or symptoms of depression during treatment. Those allergic to pregabalin or any of its components should not take this medication. Diabetic patients may be affected by weight gain in terms of blood sugar control, so dose adjustments for diabetes medications may be necessary. If serious allergic reactions occur, such as angioedema, treatment should be discontinued immediately and healthcare professionals should be notified. Elderly patients may experience increased dizziness or drowsiness, posing a risk of falls, so caution is especially necessary at the beginning of treatment. Some patients may experience blurred vision or changes in vision; if these symptoms occur, consult a physician. When discontinuing this medication, withdrawal symptoms such as insomnia, headache, or anxiety may occur, so sudden cessation should be avoided. Patients with a history of drug abuse may be at higher risk for abusing this medication, and caution is needed during use. Patients with decreased kidney function require dose adjustments, and it is not recommended for dialysis patients. Patients with heart disease should use this medication cautiously due to risks such as congestive heart failure. This medication has central nervous system depressant effects, and caution is needed when taken with opioids or other drugs that may increase the risk of respiratory depression. During early pregnancy, there may be a risk of congenital abnormalities in the fetus, so pregnant women are advised not to take it, and women of childbearing age should use effective contraception. It is recommended that breastfeeding women discontinue breastfeeding or the medication itself, as the drug can be passed through breast milk. Engaging in activities such as driving or operating machinery may pose an accident risk due to dizziness or drowsiness, so these activities should be avoided if such symptoms occur after taking the medication. In the event of an overdose, symptoms such as confusion, drowsiness, or seizures may occur, so immediate medical attention is required. This medication should be stored out of reach of children, and transferring to other containers should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to keep it at room temperature between 1 degree and 30 degrees Celsius.
Pink almond-shaped film-coated extended-release tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 330mg
Tablet · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.